Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • M&A / Deals
  • Arcera and Fosun sign MoU for neuroscience innovation
  • M&A / Deals

Arcera and Fosun sign MoU for neuroscience innovation

Pharmaceutical Business Review

The initiative aligns with China's and the United Arab Emirates' (UAE) broader strategic objectives to enhance healthcare and the life sciences industry.

Neuroscience

Read full story

pharminent April 29, 2026 (Last updated: April 29, 2026)

Pharmaceutical Business Review

The initiative aligns with China’s and the United Arab Emirates’ (UAE) broader strategic objectives to enhance healthcare and the life sciences industry.

Neuroscience

Read full story

Post navigation

Previous: Rocket to sell PRV for $180m to advance gene therapy pipeline
Next: Novartis’ Q1 sales miss hints at industry’s utilisation of M&A remedies

Related Stories

  • M&A / Deals

BioMarin spends up to $490m for Alesta’s bone disease candidate

pharminent August 19, 2026
  • M&A / Deals

J&J hands lymphoma bispecific CAR T back to AbelZeta

pharminent August 17, 2026
  • M&A / Deals

Novo Nordisk and AWS form AI partnership to speed drug discovery

pharminent August 17, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.